CN105934255A - 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法 - Google Patents

用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法 Download PDF

Info

Publication number
CN105934255A
CN105934255A CN201480072891.XA CN201480072891A CN105934255A CN 105934255 A CN105934255 A CN 105934255A CN 201480072891 A CN201480072891 A CN 201480072891A CN 105934255 A CN105934255 A CN 105934255A
Authority
CN
China
Prior art keywords
inhibitor
pharmaceutically acceptable
methyl
chlorophenyl
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480072891.XA
Other languages
English (en)
Chinese (zh)
Inventor
S.凯内皮尔
J.卡农
P.休斯
J.D.奥利纳
R.J.里克尔斯
A.Y.塞基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN202011275297.4A priority Critical patent/CN112933236A/zh
Publication of CN105934255A publication Critical patent/CN105934255A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201480072891.XA 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法 Pending CN105934255A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011275297.4A CN112933236A (zh) 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361902717P 2013-11-11 2013-11-11
US61/902717 2013-11-11
PCT/US2014/065034 WO2015070224A2 (en) 2013-11-11 2014-11-11 Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011275297.4A Division CN112933236A (zh) 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法

Publications (1)

Publication Number Publication Date
CN105934255A true CN105934255A (zh) 2016-09-07

Family

ID=52001089

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480072891.XA Pending CN105934255A (zh) 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法
CN202011275297.4A Pending CN112933236A (zh) 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202011275297.4A Pending CN112933236A (zh) 2013-11-11 2014-11-11 用于治疗癌症的包括mdm2抑制剂和一种或多种另外的药物活性剂的组合疗法

Country Status (33)

Country Link
US (3) US20160287569A1 (https=)
EP (2) EP3068393B9 (https=)
JP (5) JP2016535795A (https=)
KR (3) KR20220167335A (https=)
CN (2) CN105934255A (https=)
AP (1) AP2016009243A0 (https=)
AU (3) AU2014346354A1 (https=)
BR (1) BR112016010564A2 (https=)
CA (1) CA2930244A1 (https=)
CL (1) CL2016001131A1 (https=)
CY (1) CY1125358T1 (https=)
DK (1) DK3068393T5 (https=)
EA (2) EA202092456A3 (https=)
ES (1) ES2916721T3 (https=)
HR (1) HRP20220718T1 (https=)
HU (1) HUE059351T2 (https=)
IL (2) IL245568B (https=)
LT (1) LT3068393T (https=)
MA (1) MA39094B1 (https=)
MX (6) MX378969B (https=)
MY (1) MY192088A (https=)
NZ (2) NZ720766A (https=)
PH (1) PH12016500871A1 (https=)
PL (1) PL3068393T3 (https=)
PT (1) PT3068393T (https=)
RS (1) RS63348B9 (https=)
SG (1) SG10201902429PA (https=)
SI (1) SI3068393T1 (https=)
SM (1) SMT202200241T1 (https=)
TN (1) TN2016000176A1 (https=)
UA (1) UA120750C2 (https=)
WO (1) WO2015070224A2 (https=)
ZA (1) ZA201603342B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843329A (zh) * 2016-10-17 2019-06-04 第一三共株式会社 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2025098488A1 (zh) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
HRP20220718T1 (hr) * 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3341023A1 (en) * 2015-08-28 2018-07-04 Novartis AG Combination therapy using pi3k inhbitor and mdm2 inhibitor
RU2020142739A (ru) * 2015-08-28 2021-01-15 Новартис Аг Ингибиторы mdm2 и их комбинации
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
IL308399B2 (en) * 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3927344A4 (en) * 2018-12-11 2023-01-18 Kartos Therapeutics METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION
US12194024B2 (en) 2019-07-26 2025-01-14 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
US20230218575A1 (en) * 2020-06-15 2023-07-13 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeautic applications thereof
WO2022036067A1 (en) * 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Combination therapies for use in treating cancer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
EP4719409A1 (en) * 2023-06-05 2026-04-08 Kartos Therapeutics, Inc. Treatment of endometrial cancer with mdm2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180296A (zh) * 2010-06-04 2013-06-26 安姆根有限公司 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物
WO2013139724A1 (en) * 2012-03-19 2013-09-26 F. Hoffmann-La Roche Ag Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
EA012181B1 (ru) 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
RS53151B (sr) 2007-03-23 2014-06-30 Amgen Inc. 3-supstituisani derivati hinolina ili hinoksalina i njihova upotreba kao inhibitora fosfatidilinozitol 3-kinaze (pi3k)
EA017389B1 (ru) 2007-03-23 2012-12-28 Амген Инк. Гетероциклические соединения и их применение
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008153947A2 (en) 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
AU2010216239B2 (en) 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2011012037A (es) 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
EP2445902A2 (en) 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
EA201270013A1 (ru) 2009-06-25 2012-06-29 Амген Инк. Гетероциклические соединения и их применение
HUE024568T2 (hu) 2009-09-11 2016-02-29 Amgen Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin antimitotikus szerre rezisztens rák kezelésében történõ alkalmazásra
KR20120031734A (ko) * 2010-09-27 2012-04-04 삼성전자주식회사 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
WO2012106299A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN104428001A (zh) 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
US20160002185A1 (en) 2013-02-19 2016-01-07 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
CA2902856C (en) 2013-02-28 2021-02-16 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
CN105358530A (zh) * 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
KR20160037233A (ko) 2013-07-26 2016-04-05 베링거 인겔하임 인터내셔날 게엠베하 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브
HRP20220718T1 (hr) * 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180296A (zh) * 2010-06-04 2013-06-26 安姆根有限公司 用于治疗癌症的作为mdm2抑制剂的哌啶酮衍生物
WO2013139724A1 (en) * 2012-03-19 2013-09-26 F. Hoffmann-La Roche Ag Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
H. JEAN KHOURY ET AL.: "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and or nilotinib therapy failure", 《BLOOD》 *
JOSEPH M. GOZGIT ET AL.: ""Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies", 《MOL CANCER THER》 *
WEIGUO ZHANG ET AL.: "Blockade of MEK and MDM2 synergistically induces apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim", 《CANCER RESEARCH》 *
ZHENYU JI ET AL.: "p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiated Mek Inhibition", 《JOURNAL OF INVESTIGATIVE DERMATOLOGY》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843329A (zh) * 2016-10-17 2019-06-04 第一三共株式会社 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用
WO2025098488A1 (zh) * 2023-11-09 2025-05-15 深圳艾欣达伟医药科技有限公司 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症

Also Published As

Publication number Publication date
US10881648B2 (en) 2021-01-05
AU2020201321A1 (en) 2020-03-12
JP2021004259A (ja) 2021-01-14
MX2016006025A (es) 2016-12-02
US20190290630A1 (en) 2019-09-26
CN112933236A (zh) 2021-06-11
NZ758548A (en) 2022-02-25
LT3068393T (lt) 2022-08-10
US20220280495A1 (en) 2022-09-08
JP2019142916A (ja) 2019-08-29
EP3068393B1 (en) 2022-03-09
MX2020013670A (es) 2022-09-30
CY1125358T1 (el) 2024-09-20
AU2014346354A1 (en) 2016-05-26
MX391859B (es) 2025-03-12
MX393610B (es) 2025-03-24
HUE059351T2 (hu) 2022-11-28
PT3068393T (pt) 2022-06-14
JP6972274B2 (ja) 2021-11-24
JP2022009805A (ja) 2022-01-14
KR102305351B1 (ko) 2021-09-24
EA201690980A1 (ru) 2016-09-30
CA2930244A1 (en) 2015-05-14
RS63348B9 (sr) 2022-10-31
WO2015070224A2 (en) 2015-05-14
EA202092456A3 (ru) 2021-09-30
JP2016535795A (ja) 2016-11-17
TN2016000176A1 (en) 2017-10-06
US20160287569A1 (en) 2016-10-06
DK3068393T3 (da) 2022-06-13
CL2016001131A1 (es) 2017-04-17
AP2016009243A0 (en) 2016-05-31
HRP20220718T1 (hr) 2022-09-30
MX2022008175A (es) 2022-08-15
ZA201603342B (en) 2025-04-30
RS63348B1 (sr) 2022-07-29
KR102473485B1 (ko) 2022-12-01
MX2020001550A (es) 2022-04-26
BR112016010564A2 (pt) 2017-10-10
EP3068393A2 (en) 2016-09-21
AU2022201495A1 (en) 2022-03-24
IL245568A0 (en) 2016-06-30
KR20160074012A (ko) 2016-06-27
SG10201902429PA (en) 2019-04-29
ES2916721T3 (es) 2022-07-05
EP4039256A1 (en) 2022-08-10
MA39094B1 (fr) 2020-06-30
KR20220167335A (ko) 2022-12-20
KR20210119550A (ko) 2021-10-05
AU2020201321B2 (en) 2022-03-10
EA036942B1 (ru) 2021-01-18
SMT202200241T1 (it) 2022-09-14
SI3068393T1 (sl) 2022-11-30
PH12016500871A1 (en) 2016-07-04
UA120750C2 (uk) 2020-02-10
IL285646A (en) 2021-09-30
MA39094A1 (fr) 2018-07-31
PL3068393T3 (pl) 2022-10-03
IL245568B (en) 2021-09-30
MY192088A (en) 2022-07-26
JP2023033414A (ja) 2023-03-10
MX2022012320A (es) 2022-10-27
MX378969B (es) 2025-03-11
MX2019009853A (es) 2019-10-14
EP3068393B9 (en) 2022-07-20
WO2015070224A3 (en) 2015-08-13
EA202092456A2 (ru) 2021-05-31
DK3068393T5 (da) 2022-08-22
NZ720766A (en) 2022-02-25

Similar Documents

Publication Publication Date Title
US10881648B2 (en) Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
JP6880101B2 (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
JP2025084856A (ja) 製造方法及びｍｄｍ２阻害剤の結晶形
US12295939B2 (en) Substituted benzothiophene analogs as selective estrogen receptor degraders
EP3929188A1 (en) Pd-l1 antagonist compound
CN115066423B (zh) Pd-l1拮抗剂化合物
HK40078013A (en) Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia
CN121652170A (zh) 卤代亚烷基取代环烷基或杂环基类抑制剂及其制备方法和应用
HK1228256B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK1228256A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
HK40058270A (en) Pd-l1 antagonist compound
HK1226052B (en) Crystalline form of a mdm2 inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160907